Latest Articles
Advanced Endometrial Cancer Pipeline Outlook Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape - Barchart.com
Advanced Endometrial Cancer Pipeline Outlook Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape Barchart.com
Published: Aug. 12, 2025, 10:38 p.m.
Breakthrough treatment combines immunotherapy and chemotherapy - National Health Executive
Breakthrough treatment combines immunotherapy and chemotherapy National Health Executive
Published: Aug. 7, 2025, 8:48 a.m.
Breakthrough: New Cancer Drug Ampligen Delivers Promising Results in Pancreatic, Ovarian, and Breast Cancer Trials - Stock Titan
Breakthrough: New Cancer Drug Ampligen Delivers Promising Results in Pancreatic, Ovarian, and Breast Cancer Trials Stock Titan
Published: Aug. 6, 2025, 1 p.m.
Advancements and Breakthroughs in Endometrial Cancer Screening: A Current Overview - BIOENGINEER.ORG
Advancements and Breakthroughs in Endometrial Cancer Screening: A Current Overview BIOENGINEER.ORG
Published: July 31, 2025, 7:30 p.m.
CIAPIN1 promotes survival, proliferation, migration and glycolysis of endometrial cancer cells through PI3K/Akt pathway - Nature
CIAPIN1 promotes survival, proliferation, migration and glycolysis of endometrial cancer cells through PI3K/Akt pathway Nature
Published: July 30, 2025, 1:56 a.m.
Local Discovery, Global Collaboration Fuel STI Breakthrough - Mirage News
Local Discovery, Global Collaboration Fuel STI Breakthrough Mirage News
Published: July 24, 2025, 2:10 a.m.
Breakthrough Menstrual Blood Test Detects Endometriosis In 10 Minutes - Study Finds
Breakthrough Menstrual Blood Test Detects Endometriosis In 10 Minutes Study Finds
Published: July 23, 2025, 8:24 p.m.
Breakthrough Cancer Data: Genmab Reveals First Rina-S Results for Deadly Endometrial Cancer at ASCO 2025 - Stock Titan
Breakthrough Cancer Data: Genmab Reveals First Rina-S Results for Deadly Endometrial Cancer at ASCO 2025 Stock Titan
Published: May 22, 2025, 9:05 p.m.
Combinations Targeting PI3K/ AKT/mTOR and MAPK/ERK Pathways Are Under Study in Endometrial Cancer - OncLive
Combinations Targeting PI3K/ AKT/mTOR and MAPK/ERK Pathways Are Under Study in Endometrial Cancer OncLive
Published: May 21, 2025, 2:09 p.m.
Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Resistant Endometrial Cancer Patients - Stock Titan
Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Resistant Endometrial Cancer Patients Stock Titan
Published: May 14, 2025, 8:10 p.m.
Link copied to clipboard!